Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights:
Currently, multiple innovative BCMA-targeted treatment modalities, including antibody-drug conjugate (ADC), CAR-T cells, and bispecific T cell engager (BiTE), are under active clinical development. However, two BCMA targeted drug modalities have also entered the market. Belantamab mafodotin (Blenrep) developed by GlaxoSmithkline was the first BCMA targeted drug approved for patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. It is an antibody drug conjugate which consists of humanized anti-BCMA IgG1 monoclonal antibody conjugated to monomethyl auristatin F (MMAF, mafodotin) via a non-cleavable maleimidocaproyl (MC) linker.
In April 2021, Abecma developed by Bristol Meyer Squibb has also gain entry into market for the management of multiple myeloma. Abecma is BCMA directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy which is approved for the same indication. The entry of Abecma in the market is expected to have a negative impact on the growth of Blenrep sales which is mainly due to its novel mechanism of action, better survival rates, and ability to overcome the limitations of Blenrep. As per our analysis, Abecma will dominate the market during the forecast period. Apart from multiple myeloma, researchers are also evaluating the role of these drugs in other therapeutic conditions including AL Amyloidosis, and various subtypes of lymphoma which will further drive the growth of market. In addition, several ongoing clinical trials are also evaluating the use of Abecma in combination with other modalities including pembrolizumab, dexamethasone, and other chemotherapeutic agents which aim to enhance the efficacy of the treatment, which will boost this segment during forecast period.
The active research and development in this sector will drive the growth of the market. At present, several BCMA targeting drugs including ciltacabtagene autoleucel, Allo715, CTX-120, MCARH171, and others are present in clinical pipeline which are expected to gain approval during the forecast period. For instance, US FDA has recently granted priority review for ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy developed by Janssen. The rapid approval of these drugs during the forecast period will also drive the growth of market.
The global BCMA targeted drugs market is expected to witness high growth rates during the forecast period attributing mainly to the increase in prevalence of cancers and rates at which conventional therapies are failing. Moreover, key players in the market are strategically partnering and collaborating to expand the product portfolio and geographical presence of the company. Amid region, North America dominated the global market which is mainly credited to the growing number of research and development activities, presence of large pharmaceutical sector and high adoption rates of already approved therapies. Other regions such as Europe, Asia-Pacific are also expected to grow at high rates due to increase in prevalence of disorders and rising awareness among the population.
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights:
- Research Methodology
- Global & Regional Market Analysis
- Global BCMA Targeted Drugs Market Opportunity Assessment: > USD 4 Billion
- Market and Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 2 Drugs
- Approved BCMA Targeted Drugs Patent, Price and Sales insight 2020 Till 2026
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
Currently, multiple innovative BCMA-targeted treatment modalities, including antibody-drug conjugate (ADC), CAR-T cells, and bispecific T cell engager (BiTE), are under active clinical development. However, two BCMA targeted drug modalities have also entered the market. Belantamab mafodotin (Blenrep) developed by GlaxoSmithkline was the first BCMA targeted drug approved for patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. It is an antibody drug conjugate which consists of humanized anti-BCMA IgG1 monoclonal antibody conjugated to monomethyl auristatin F (MMAF, mafodotin) via a non-cleavable maleimidocaproyl (MC) linker.
In April 2021, Abecma developed by Bristol Meyer Squibb has also gain entry into market for the management of multiple myeloma. Abecma is BCMA directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy which is approved for the same indication. The entry of Abecma in the market is expected to have a negative impact on the growth of Blenrep sales which is mainly due to its novel mechanism of action, better survival rates, and ability to overcome the limitations of Blenrep. As per our analysis, Abecma will dominate the market during the forecast period. Apart from multiple myeloma, researchers are also evaluating the role of these drugs in other therapeutic conditions including AL Amyloidosis, and various subtypes of lymphoma which will further drive the growth of market. In addition, several ongoing clinical trials are also evaluating the use of Abecma in combination with other modalities including pembrolizumab, dexamethasone, and other chemotherapeutic agents which aim to enhance the efficacy of the treatment, which will boost this segment during forecast period.
The active research and development in this sector will drive the growth of the market. At present, several BCMA targeting drugs including ciltacabtagene autoleucel, Allo715, CTX-120, MCARH171, and others are present in clinical pipeline which are expected to gain approval during the forecast period. For instance, US FDA has recently granted priority review for ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy developed by Janssen. The rapid approval of these drugs during the forecast period will also drive the growth of market.
The global BCMA targeted drugs market is expected to witness high growth rates during the forecast period attributing mainly to the increase in prevalence of cancers and rates at which conventional therapies are failing. Moreover, key players in the market are strategically partnering and collaborating to expand the product portfolio and geographical presence of the company. Amid region, North America dominated the global market which is mainly credited to the growing number of research and development activities, presence of large pharmaceutical sector and high adoption rates of already approved therapies. Other regions such as Europe, Asia-Pacific are also expected to grow at high rates due to increase in prevalence of disorders and rising awareness among the population.
1. INTRODUCTION TO BCMA TARGETING THERAPY
1.1 Overview
1.2 History of BCMA Targeting Therapeutics
2. BCMA TARGETING THERAPEUTICS MECHANISM OF ACTION
3. BCMA AS IDEAL TARGET FOR HEMATOLOGICAL CANCER
4. GLOBAL BCMA TARGETING DRUGS MARKET ANALYSIS
4.1 Overview
4.2 Future Opportunity
5. GLOBAL BCMA TARGETING DRUGS MARKET OPPORTUNITY BY REGION
5.1 US
5.2 Europe
5.3 Japan
5.4 Rest of World
6. GLOBAL BCMA TARGETING DRUGS MARKET BY CANCER TYPE
6.1 Multiple Myeloma
6.2 Lymphoma
6.3 Leukemia
7. BLENREP (BELANTAMAB MAFODOTIN-BLMF) - FIRST APPROVED BCMA TARGETING THERAPY
7.1 Overview
7.2 Dosage & Price Analysis
7.3 Sales Analysis
8. ABECMA (IDECABTAGENE VICLEUCEL) - SECOND APPROVED BCMA TARGETING THERAPY
8.1 Overview
8.2 Dosage, Price & Sales Analysis
9. BCMA TARGETING DRUGS SALES FORECAST 2026
9.1 Blenrep
9.2 Abecma
10. BCMA TARGETING DRUGS CLINICAL TRIALS INSIGHT
10.1 By Phase
10.2 By Development Status
10.3 By Region
11. BCMA TARGETING DRUGS MARKET - ONGOING RESEARCH & DEVELOPMENT
11.1 Ciltacabtagene Autoleucel (JNJ-68284528)
11.2 Allo715
11.3 CTX120
11.4 C-CAR088
11.5 CT053
11.6 HPN217
11.7 Pacanalotamab (AMG 420/ BI 836909)
11.8 PHE
11.9 bb21217
11.10 SEA BCMA
12. GLOBAL BCMA TARGETED DRUGS CLINICAL TRIALS INSIGHT
12.1 Research
12.2 Preclinical
12.3 Clinical
12.4 Phase-0
12.5 Phase-I
12.6 Phase-I/II
12.7 Phase-II
12.8 Phase-II/III
12.9 Phase-III
12.10 Preregistration
13. APPROVED BCMA TARGETED DRUGS CLINICAL INSOGHT
13.1 Belantamab Mafodotin - GlaxoSmithKline
13.2 Idecabtagene Vicleucel - Bluebird Bio/Celgene Corporation
14. GLOBAL BCMA TARGETING DRUG MARKET DYNAMICS
14.1 Market Drivers
14.2 Market Challenges
15. GLOBAL BCMA TARGETING DRUG MARKET FUTURE OUTLOOK
16. COMPETITIVE LANDSCAPE
16.1 Allogene Therapeutics
16.2 AbbVie
16.3 Amgen
16.4 BioTherapeutics
16.5 Bluebird Bio
16.6 Bristol Mayer Squibb
16.7 Carsgen Therapeutics
16.8 Celgene
16.9 Cogent Bioscience
16.10 CRISPR Therapeutics
16.11 GlaxoSmithKline
16.12 Harpoon Therapeutics
16.13 Hrain Biotechnology
16.14 iCell Gene Therapeutics
16.15 Johnson & Johnson
16.16 Juno Therapeutics
16.17 Novartis
16.18 Poseida Therapeutics
16.19 Seagen
16.20 Seattle Genetics
1.1 Overview
1.2 History of BCMA Targeting Therapeutics
2. BCMA TARGETING THERAPEUTICS MECHANISM OF ACTION
3. BCMA AS IDEAL TARGET FOR HEMATOLOGICAL CANCER
4. GLOBAL BCMA TARGETING DRUGS MARKET ANALYSIS
4.1 Overview
4.2 Future Opportunity
5. GLOBAL BCMA TARGETING DRUGS MARKET OPPORTUNITY BY REGION
5.1 US
5.2 Europe
5.3 Japan
5.4 Rest of World
6. GLOBAL BCMA TARGETING DRUGS MARKET BY CANCER TYPE
6.1 Multiple Myeloma
6.2 Lymphoma
6.3 Leukemia
7. BLENREP (BELANTAMAB MAFODOTIN-BLMF) - FIRST APPROVED BCMA TARGETING THERAPY
7.1 Overview
7.2 Dosage & Price Analysis
7.3 Sales Analysis
8. ABECMA (IDECABTAGENE VICLEUCEL) - SECOND APPROVED BCMA TARGETING THERAPY
8.1 Overview
8.2 Dosage, Price & Sales Analysis
9. BCMA TARGETING DRUGS SALES FORECAST 2026
9.1 Blenrep
9.2 Abecma
10. BCMA TARGETING DRUGS CLINICAL TRIALS INSIGHT
10.1 By Phase
10.2 By Development Status
10.3 By Region
11. BCMA TARGETING DRUGS MARKET - ONGOING RESEARCH & DEVELOPMENT
11.1 Ciltacabtagene Autoleucel (JNJ-68284528)
11.2 Allo715
11.3 CTX120
11.4 C-CAR088
11.5 CT053
11.6 HPN217
11.7 Pacanalotamab (AMG 420/ BI 836909)
11.8 PHE
11.9 bb21217
11.10 SEA BCMA
12. GLOBAL BCMA TARGETED DRUGS CLINICAL TRIALS INSIGHT
12.1 Research
12.2 Preclinical
12.3 Clinical
12.4 Phase-0
12.5 Phase-I
12.6 Phase-I/II
12.7 Phase-II
12.8 Phase-II/III
12.9 Phase-III
12.10 Preregistration
13. APPROVED BCMA TARGETED DRUGS CLINICAL INSOGHT
13.1 Belantamab Mafodotin - GlaxoSmithKline
13.2 Idecabtagene Vicleucel - Bluebird Bio/Celgene Corporation
14. GLOBAL BCMA TARGETING DRUG MARKET DYNAMICS
14.1 Market Drivers
14.2 Market Challenges
15. GLOBAL BCMA TARGETING DRUG MARKET FUTURE OUTLOOK
16. COMPETITIVE LANDSCAPE
16.1 Allogene Therapeutics
16.2 AbbVie
16.3 Amgen
16.4 BioTherapeutics
16.5 Bluebird Bio
16.6 Bristol Mayer Squibb
16.7 Carsgen Therapeutics
16.8 Celgene
16.9 Cogent Bioscience
16.10 CRISPR Therapeutics
16.11 GlaxoSmithKline
16.12 Harpoon Therapeutics
16.13 Hrain Biotechnology
16.14 iCell Gene Therapeutics
16.15 Johnson & Johnson
16.16 Juno Therapeutics
16.17 Novartis
16.18 Poseida Therapeutics
16.19 Seagen
16.20 Seattle Genetics
LIST OF FIGURES
Figure 1-1: Evolution of BCMA Targeting Therapeutics
Figure 2-1: BCMA Signaling Pathways
Figure 2-2: BCMA Targeting Therapeutics – Mechanism of Action
Figure 2-3: Blenrep - Mechanism of Action
Figure 2-4: Abecma - Mechanism of Action
Figure 3-1: Role of BCMA in Cell Cycle Signaling Pathway Regulation
Figure 3-2: Strategies For Targeting BCMA
Figure 3-3: Role of BCMA in Cancer
Figure 4-1: Global – Newly Diagnosed Leukemia Cases, 2020 - 2026
Figure 4-2: Global – Newly Diagnosed Hodgkin’s Lymphoma Cases, 2020 - 2026
Figure 4-3: Global – Newly Diagnosed Non-Hodgkin’s Lymphoma Cases, 2020 - 2026
Figure 4-4: Global – Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
Figure 4-5: Global – BCMA Targeting Therapy, Blood Cancer Therapeutics & Multiple Myeloma Therapeutics Market (US$ Billion), 2020
Figure 4-6: Global – BCMA Targeting Therapy Market Opportunity (US$ Million), 2020-2026
Figure 4-7: Global – Blood Cancer Drug Market Opportunity (US$ Billion), 2020-2026
Figure 4-8: Global – Multiple Myeloma Drug Market Opportunity (US$ Billion), 2020-2026
Figure 4-9: Global – BCMA Targeting Therapy Market by Product (%) 2026
Figure 5-1: US – Newly Diagnosed Leukemia Cases, 2020 - 2026
Figure 5-2: US – Newly Diagnosed Hodgkin’s Lymphoma Cases, 2020 - 2026
Figure 5-3: US – Newly Diagnosed Non-Hodgkin’s Lymphoma Cases, 2020 - 2026
Figure 5-4: US – Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
Figure 5-5: US – BCMA Targeting Therapy Market Opportunity (US$ Million), 2020-2026
Figure 5-6: US – BCMA Targeting Therapy Market by Product (%), 2026
Figure 5-7: Europe – Newly Diagnosed Leukemia Cases, 2020 - 2026
Figure 5-8: Europe – Newly Diagnosed Non-Hodgkin’s Lymphoma Cases, 2020 - 2026
Figure 5-9: Europe – Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
Figure 5-10: Europe – BCMA Targeting Therapy Market Opportunity (US$ Million), 2020-2026
Figure 5-11: Europe – BCMA Targeting Therapy Market by Product (%), 2026
Figure 5-12: Japan – Newly Diagnosed Leukemia Cases, 2020 - 2026
Figure 5-13: Japan – Newly Diagnosed Hodgkin’s Lymphoma Cases, 2020 - 2026
Figure 5-14: Japan – Newly Diagnosed Non-Hodgkin’s Lymphoma Cases, 2020 - 2026
Figure 5-15: Japan – Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
Figure 5-16: Japan – BCMA Targeting Therapy Market Opportunity (US$ Million), 2022-2026
Figure 5-17: Japan – BCMA Targeting Therapy Market by Product (%), 2026
Figure 5-18: ROW – BCMA Targeting Therapy Market Opportunity (US$ Million), 2021 -2026
Figure 5-19: ROW – BCMA Targeting Therapy Market by Product (%), 2026
Figure 5-20: ROW – BCMA Targeting Therapy Market Share by Countries (%), 2026
Figure 6-1: Global – Number of Multiple Myeloma Cases, 2021-2026
Figure 6-2: Global – Multiple Myeloma Targeting BCMA Targeting Therapeutics Market Oportunity (US$ Million), 2021 - 2026
Figure 6-3: Global – Number of NHL Cases, 2021-2026
Figure 6-4: Global – Number of Hodgkin’s Lymphoma Cases, 2021-2026
Figure 6-5: Global – BCMA Targeting Therapeutics Market Opportunity in Lymphoma (US$ Million), 2025 & 2026
Figure 6-6: Global – Number of Newly Diagnosed Leukemia Cases, 2021-2026
Figure 6-7: Global – BCMA Targeting Therapeutics Market Opportunity in Leukemia (US$ Million), 2025 & 2026
Figure 7-1: US - Blenrep FDA Approval & Orphan Designation Year
Figure 7-2: Europe - Blenrep EMA Approval & Orphan Designation Year
Figure 7-3: US - Price for 100mg Supply & Price for Single Treatment Cycle using Blenrep (US$), November’2021
Figure 7-4: Europe - Price for 100mg Supply & Price for Single Treatment Cycle using Blenrep (GBP), November’2021
Figure 7-5: Blenrep – Initial & Reduced Dose (mg/kg/3 Week)
Figure 7-6: Global - Blenrep Quarterly Sales Value (US$/GBP Million), Q1 – Q3, 2021
Figure 7-7: US - Blenrep Quarterly Sales Value (US$/GBP Million), Q1 – Q3, 2021
Figure 7-8: Europe - Blenrep Quarterly Sales Value (US$/GBP Million), Q1 – Q3, 2021
Figure 7-9: Global - Blenrep Sales Value by Region (US$/GBP Million), H1 2021
Figure 7-10: Global – Blenrep Half Yearly Sales Share by Region (%), H1 2021
Figure 7-11: Global - Blenrep Quarterly Sales Value by Region (US$/GBP Million), Q3, 2021
Figure 7-12: Global – Blenrep Quarterly Yearly Sales Share by Region (%), Q3, 2021
Figure 7-13: Global - Blenrep Quarterly Sales Value (US$/GBP Million), Q3 & Q4, 2020
Figure 7-14: US - Blenrep Quarter Sales Value (US$/GBP Million), Q3 & Q4, 2020
Figure 7-15: Europe - Blenrep Quarter Sales Value (US$/GBP Million), Q3 & Q4, 2020
Figure 7-16: Global - Blenrep Annual Sales Value by Region (US$/GBP Million), 2020
Figure 7-17: Global - Blenrep Sales Share in by Region (%), 2020
Figure 8-1: US - Abecma FDA Approval & Orphan Designation Year
Figure 8-2: Europe - Abecma EMA Approval & Orphan Designation Year
Figure 8 3: Abecma – Minimum & Maximum Dosage of CAR Positive Viable T Cells (Million ells), November’2021
Figure 8-4: Global - Abecma Quarterly Sales Value (US$ Million), Q2 & Q3, 2021
Figure 9-1: Global - Blenrep Sales Forecast (US$ Million), 2021 - 2026
Figure 9-2: US - Blenrep Sales Forecast (US$ Million), 2021 - 2026
Figure 9-3: Europe - Blenrep Sales Forecast (US$ Million), 2022 - 2026
Figure 9-4: Japan - Blenrep Sales Forecast (US$ Million), 2022 - 2026
Figure 9-5: ROW - Blenrep Sales Forecast (US$ Million), 2022 - 2026
Figure 9-6: Global - Abecma Sales Forecast (US$ Million), 2021 - 2026
Figure 9-7: US - Abecma Sales Forecast (US$ Million), 2021 - 2026
Figure 9-8: Europe - Abecma Sales Forecast (US$ Million), 2022 - 2026
Figure 9-9: Japan - Abecma Sales Forecast (US$ Million), 2022 - 2026
Figure 9-10: ROW - Abecma Sales Forecast (US$ Million), 2022 - 2026
Figure 10-1: Global – Number of BCMA Related Clinical Trials by Phase, November’2021
Figure 10-2: Global – BCMA Related Clinical Trials by Phase, November’2021
Figure 10-3: Global – Number of BCMA Related Clinical Trials by Development Status, November’2021
Figure 10-4: Global – Number of BCMA Related Clinical Trials by Development Status (%), November’2021
Figure 10-5: Global – Number of BCMA Related Clinical Trials by Region, November’2021
Figure 11-1: Investigational BCMA Targeting Therapeutics
Figure 11-2: CARTITUDE 1 Trial – Study Initiation & Completion Year
Figure 11-3: CARTITUDE 2 Trial – Study Initiation & Completion Year
Figure 11-4: CARTITUDE 4 Trial – Study Initiation & Completion Year
Figure 11-5: ALLO715 Phase I Trial – Study Initiation & Completion Year
Figure 11-6: CTX120 Phase I Trial – Study Initiation & Completion Year
Figure 11-7: C CAR088 Phase I Trial – Study Initiation & Completion Year
Figure 11-8: CT053 Phase II Trial – Study Initiation & Completion Year
Figure 11-9: CT053 Phase I Trial – Study Initiation & Completion Year
Figure 11-10: HPN217 Phase I Trial – Study Initiation & Completion Year
Figure 11-11: AMG 420 Phase I Trial – Study Initiation & Completion Year
Figure 11-12: PHE 885 Phase I Trial – Study Initiation & Completion Year
Figure 11-13: bb21217 Phase I Trial – Study Initiation & Completion Year
Figure 11-14: SEA BCMA Phase I Trial – Study Initiation & Completion Year
Figure 12-1: Global – number of BCMA Targeted Drug in Clinical trials, 2021 -2026
Figure 14-1: Global BCMA Targeting Therapy Market Drivers
Figure 14-2: Challenges for Global BCMA Targeting Therapy Market
Figure 14-3: US – Annual Cost Comparison of BCMA Targeting Therapy with other Treatments (US$), September’2021
Figure 1-1: Evolution of BCMA Targeting Therapeutics
Figure 2-1: BCMA Signaling Pathways
Figure 2-2: BCMA Targeting Therapeutics – Mechanism of Action
Figure 2-3: Blenrep - Mechanism of Action
Figure 2-4: Abecma - Mechanism of Action
Figure 3-1: Role of BCMA in Cell Cycle Signaling Pathway Regulation
Figure 3-2: Strategies For Targeting BCMA
Figure 3-3: Role of BCMA in Cancer
Figure 4-1: Global – Newly Diagnosed Leukemia Cases, 2020 - 2026
Figure 4-2: Global – Newly Diagnosed Hodgkin’s Lymphoma Cases, 2020 - 2026
Figure 4-3: Global – Newly Diagnosed Non-Hodgkin’s Lymphoma Cases, 2020 - 2026
Figure 4-4: Global – Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
Figure 4-5: Global – BCMA Targeting Therapy, Blood Cancer Therapeutics & Multiple Myeloma Therapeutics Market (US$ Billion), 2020
Figure 4-6: Global – BCMA Targeting Therapy Market Opportunity (US$ Million), 2020-2026
Figure 4-7: Global – Blood Cancer Drug Market Opportunity (US$ Billion), 2020-2026
Figure 4-8: Global – Multiple Myeloma Drug Market Opportunity (US$ Billion), 2020-2026
Figure 4-9: Global – BCMA Targeting Therapy Market by Product (%) 2026
Figure 5-1: US – Newly Diagnosed Leukemia Cases, 2020 - 2026
Figure 5-2: US – Newly Diagnosed Hodgkin’s Lymphoma Cases, 2020 - 2026
Figure 5-3: US – Newly Diagnosed Non-Hodgkin’s Lymphoma Cases, 2020 - 2026
Figure 5-4: US – Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
Figure 5-5: US – BCMA Targeting Therapy Market Opportunity (US$ Million), 2020-2026
Figure 5-6: US – BCMA Targeting Therapy Market by Product (%), 2026
Figure 5-7: Europe – Newly Diagnosed Leukemia Cases, 2020 - 2026
Figure 5-8: Europe – Newly Diagnosed Non-Hodgkin’s Lymphoma Cases, 2020 - 2026
Figure 5-9: Europe – Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
Figure 5-10: Europe – BCMA Targeting Therapy Market Opportunity (US$ Million), 2020-2026
Figure 5-11: Europe – BCMA Targeting Therapy Market by Product (%), 2026
Figure 5-12: Japan – Newly Diagnosed Leukemia Cases, 2020 - 2026
Figure 5-13: Japan – Newly Diagnosed Hodgkin’s Lymphoma Cases, 2020 - 2026
Figure 5-14: Japan – Newly Diagnosed Non-Hodgkin’s Lymphoma Cases, 2020 - 2026
Figure 5-15: Japan – Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
Figure 5-16: Japan – BCMA Targeting Therapy Market Opportunity (US$ Million), 2022-2026
Figure 5-17: Japan – BCMA Targeting Therapy Market by Product (%), 2026
Figure 5-18: ROW – BCMA Targeting Therapy Market Opportunity (US$ Million), 2021 -2026
Figure 5-19: ROW – BCMA Targeting Therapy Market by Product (%), 2026
Figure 5-20: ROW – BCMA Targeting Therapy Market Share by Countries (%), 2026
Figure 6-1: Global – Number of Multiple Myeloma Cases, 2021-2026
Figure 6-2: Global – Multiple Myeloma Targeting BCMA Targeting Therapeutics Market Oportunity (US$ Million), 2021 - 2026
Figure 6-3: Global – Number of NHL Cases, 2021-2026
Figure 6-4: Global – Number of Hodgkin’s Lymphoma Cases, 2021-2026
Figure 6-5: Global – BCMA Targeting Therapeutics Market Opportunity in Lymphoma (US$ Million), 2025 & 2026
Figure 6-6: Global – Number of Newly Diagnosed Leukemia Cases, 2021-2026
Figure 6-7: Global – BCMA Targeting Therapeutics Market Opportunity in Leukemia (US$ Million), 2025 & 2026
Figure 7-1: US - Blenrep FDA Approval & Orphan Designation Year
Figure 7-2: Europe - Blenrep EMA Approval & Orphan Designation Year
Figure 7-3: US - Price for 100mg Supply & Price for Single Treatment Cycle using Blenrep (US$), November’2021
Figure 7-4: Europe - Price for 100mg Supply & Price for Single Treatment Cycle using Blenrep (GBP), November’2021
Figure 7-5: Blenrep – Initial & Reduced Dose (mg/kg/3 Week)
Figure 7-6: Global - Blenrep Quarterly Sales Value (US$/GBP Million), Q1 – Q3, 2021
Figure 7-7: US - Blenrep Quarterly Sales Value (US$/GBP Million), Q1 – Q3, 2021
Figure 7-8: Europe - Blenrep Quarterly Sales Value (US$/GBP Million), Q1 – Q3, 2021
Figure 7-9: Global - Blenrep Sales Value by Region (US$/GBP Million), H1 2021
Figure 7-10: Global – Blenrep Half Yearly Sales Share by Region (%), H1 2021
Figure 7-11: Global - Blenrep Quarterly Sales Value by Region (US$/GBP Million), Q3, 2021
Figure 7-12: Global – Blenrep Quarterly Yearly Sales Share by Region (%), Q3, 2021
Figure 7-13: Global - Blenrep Quarterly Sales Value (US$/GBP Million), Q3 & Q4, 2020
Figure 7-14: US - Blenrep Quarter Sales Value (US$/GBP Million), Q3 & Q4, 2020
Figure 7-15: Europe - Blenrep Quarter Sales Value (US$/GBP Million), Q3 & Q4, 2020
Figure 7-16: Global - Blenrep Annual Sales Value by Region (US$/GBP Million), 2020
Figure 7-17: Global - Blenrep Sales Share in by Region (%), 2020
Figure 8-1: US - Abecma FDA Approval & Orphan Designation Year
Figure 8-2: Europe - Abecma EMA Approval & Orphan Designation Year
Figure 8 3: Abecma – Minimum & Maximum Dosage of CAR Positive Viable T Cells (Million ells), November’2021
Figure 8-4: Global - Abecma Quarterly Sales Value (US$ Million), Q2 & Q3, 2021
Figure 9-1: Global - Blenrep Sales Forecast (US$ Million), 2021 - 2026
Figure 9-2: US - Blenrep Sales Forecast (US$ Million), 2021 - 2026
Figure 9-3: Europe - Blenrep Sales Forecast (US$ Million), 2022 - 2026
Figure 9-4: Japan - Blenrep Sales Forecast (US$ Million), 2022 - 2026
Figure 9-5: ROW - Blenrep Sales Forecast (US$ Million), 2022 - 2026
Figure 9-6: Global - Abecma Sales Forecast (US$ Million), 2021 - 2026
Figure 9-7: US - Abecma Sales Forecast (US$ Million), 2021 - 2026
Figure 9-8: Europe - Abecma Sales Forecast (US$ Million), 2022 - 2026
Figure 9-9: Japan - Abecma Sales Forecast (US$ Million), 2022 - 2026
Figure 9-10: ROW - Abecma Sales Forecast (US$ Million), 2022 - 2026
Figure 10-1: Global – Number of BCMA Related Clinical Trials by Phase, November’2021
Figure 10-2: Global – BCMA Related Clinical Trials by Phase, November’2021
Figure 10-3: Global – Number of BCMA Related Clinical Trials by Development Status, November’2021
Figure 10-4: Global – Number of BCMA Related Clinical Trials by Development Status (%), November’2021
Figure 10-5: Global – Number of BCMA Related Clinical Trials by Region, November’2021
Figure 11-1: Investigational BCMA Targeting Therapeutics
Figure 11-2: CARTITUDE 1 Trial – Study Initiation & Completion Year
Figure 11-3: CARTITUDE 2 Trial – Study Initiation & Completion Year
Figure 11-4: CARTITUDE 4 Trial – Study Initiation & Completion Year
Figure 11-5: ALLO715 Phase I Trial – Study Initiation & Completion Year
Figure 11-6: CTX120 Phase I Trial – Study Initiation & Completion Year
Figure 11-7: C CAR088 Phase I Trial – Study Initiation & Completion Year
Figure 11-8: CT053 Phase II Trial – Study Initiation & Completion Year
Figure 11-9: CT053 Phase I Trial – Study Initiation & Completion Year
Figure 11-10: HPN217 Phase I Trial – Study Initiation & Completion Year
Figure 11-11: AMG 420 Phase I Trial – Study Initiation & Completion Year
Figure 11-12: PHE 885 Phase I Trial – Study Initiation & Completion Year
Figure 11-13: bb21217 Phase I Trial – Study Initiation & Completion Year
Figure 11-14: SEA BCMA Phase I Trial – Study Initiation & Completion Year
Figure 12-1: Global – number of BCMA Targeted Drug in Clinical trials, 2021 -2026
Figure 14-1: Global BCMA Targeting Therapy Market Drivers
Figure 14-2: Challenges for Global BCMA Targeting Therapy Market
Figure 14-3: US – Annual Cost Comparison of BCMA Targeting Therapy with other Treatments (US$), September’2021
